Literature DB >> 35114687

Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3.

Inga V Hochheiser1, Michael Pilsl2, Gregor Hagelueken1, Jonas Moecking1, Michael Marleaux1, Rebecca Brinkschulte1, Eicke Latz3, Christoph Engel2, Matthias Geyer4.   

Abstract

NLRP3 is an intracellular sensor protein that when activated by a broad spectrum of exogenous and endogenous stimuli leads to inflammasome formation and pyroptosis1,2. The conformational states of NLRP3 and the way antagonistic small molecules act at the molecular level remain poorly understood2,3. Here we report the cryo-electron microscopy structures of full-length human NLRP3 in its native form and complexed with the inhibitor CRID3 (also named MCC950)4. Inactive, ADP-bound NLRP3 is a decamer composed of homodimers of intertwined leucine-rich repeat (LRR) domains that assemble back-to-back as pentamers. The NACHT domain is located at the apical axis of this spherical structure. One pyrin domain dimer is in addition formed inside the LRR cage. Molecular contacts between the concave sites of two opposing LRR domains are mediated by an acidic loop that extends from an LRR transition segment. Binding of CRID3 considerably stabilizes the NACHT and LRR domains relative to each other. CRID3 binds into a cleft, connecting four subdomains of the NACHT with the transition LRR. Its central sulfonylurea group interacts with the Walker A motif of the NLRP3 nucleotide-binding domain and is sandwiched between two arginine residues, which explains the specificity of NLRP3 for this chemical entity. With the determination of the binding site of this key therapeutic agent, specific targeting of NLRP3 for the treatment of autoinflammatory and autoimmune diseases and rational drug optimization is within reach.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35114687     DOI: 10.1038/s41586-022-04467-w

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  44 in total

Review 1.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing.

Authors:  Ronald E Laliberte; David G Perregaux; Lise R Hoth; Philip J Rosner; Crystal K Jordan; Kevin M Peese; James F Eggler; Mark A Dombroski; Kieran F Geoghegan; Christopher A Gabel
Journal:  J Biol Chem       Date:  2003-03-06       Impact factor: 5.157

3.  NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation.

Authors:  Nan Song; Zhao-Shan Liu; Wen Xue; Zhao-Fang Bai; Qian-Yi Wang; Jiang Dai; Xin Liu; Yi-Jiao Huang; Hong Cai; Xiao-Yan Zhan; Qiu-Ying Han; Hongxia Wang; Yuan Chen; Hui-Yan Li; Ai-Ling Li; Xue-Min Zhang; Tao Zhou; Tao Li
Journal:  Mol Cell       Date:  2017-09-21       Impact factor: 17.970

Review 4.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

Review 5.  Activation and regulation of the inflammasomes.

Authors:  Eicke Latz; T Sam Xiao; Andrea Stutz
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

6.  A Genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Screen Identifies NEK7 as an Essential Component of NLRP3 Inflammasome Activation.

Authors:  Jonathan L Schmid-Burgk; Dhruv Chauhan; Tobias Schmidt; Thomas S Ebert; Julia Reinhardt; Elmar Endl; Veit Hornung
Journal:  J Biol Chem       Date:  2015-11-09       Impact factor: 5.157

Review 7.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics.

Authors:  Karen V Swanson; Meng Deng; Jenny P-Y Ting
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

8.  Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.

Authors:  Michael J Primiano; Bruce A Lefker; Michael R Bowman; Andrea G Bree; Cedric Hubeau; Paul D Bonin; Matthew Mangan; Ken Dower; Brian G Monks; Leah Cushing; Stephen Wang; Julia Guzova; Aiping Jiao; Lih-Ling Lin; Eicke Latz; David Hepworth; J Perry Hall
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

9.  NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component.

Authors:  Hexin Shi; Ying Wang; Xiaohong Li; Xiaoming Zhan; Miao Tang; Maggy Fina; Lijing Su; David Pratt; Chun Hui Bu; Sara Hildebrand; Stephen Lyon; Lindsay Scott; Jiexia Quan; Qihua Sun; Jamie Russell; Stephanie Arnett; Peter Jurek; Ding Chen; Vladimir V Kravchenko; John C Mathison; Eva Marie Y Moresco; Nancy L Monson; Richard J Ulevitch; Bruce Beutler
Journal:  Nat Immunol       Date:  2015-12-07       Impact factor: 25.606

10.  NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux.

Authors:  Yuan He; Melody Y Zeng; Dahai Yang; Benny Motro; Gabriel Núñez
Journal:  Nature       Date:  2016-01-27       Impact factor: 49.962

View more
  16 in total

Review 1.  Lipid-protein interactions regulating the canonical and the non-canonical NLRP3 inflammasome.

Authors:  Malvina Pizzuto; Pablo Pelegrin; Jean-Marie Ruysschaert
Journal:  Prog Lipid Res       Date:  2022-07-25       Impact factor: 14.673

Review 2.  NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation.

Authors:  Bo-Zong Shao; Hai-Yan Xu; Yi-Cheng Zhao; Xiao-Rui Zheng; Fang Wang; Guan-Ren Zhao
Journal:  Inflammation       Date:  2022-08-11       Impact factor: 4.657

3.  Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors.

Authors:  David Harrison; Mark G Bock; John R Doedens; Christopher A Gabel; M Katharine Holloway; Arwel Lewis; Jane Scanlon; Andrew Sharpe; Iain D Simpson; Pamela Smolak; Grant Wishart; Alan P Watt
Journal:  ACS Med Chem Lett       Date:  2022-08-01       Impact factor: 4.632

Review 4.  How location and cellular signaling combine to activate the NLRP3 inflammasome.

Authors:  Anil Akbal; Alesja Dernst; Marta Lovotti; Matthew S J Mangan; Róisín M McManus; Eicke Latz
Journal:  Cell Mol Immunol       Date:  2022-09-20       Impact factor: 22.096

Review 5.  The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Hallie M Blevins; Yiming Xu; Savannah Biby; Shijun Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

6.  Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome.

Authors:  Chao Wu; Yanqin Bian; Bingjie Lu; Dan Wang; Nisma Lena Bahaji Azami; Gang Wei; Feng Ma; Mingyu Sun
Journal:  J Transl Med       Date:  2022-06-28       Impact factor: 8.440

7.  Peste Des Petits Ruminants Virus N Protein Is a Critical Proinflammation Factor That Promotes MyD88 and NLRP3 Complex Assembly.

Authors:  Lingxia Li; Wenping Yang; Xiaoxia Ma; Jinyan Wu; Xiaodong Qin; Xiaoan Cao; Jianhua Zhou; Li Jin; Jijun He; Haixue Zheng; Xiangtao Liu; Dan Li; Youjun Shang
Journal:  J Virol       Date:  2022-05-03       Impact factor: 6.549

Review 8.  How Pyroptosis Contributes to Inflammation and Fibroblast-Macrophage Cross-Talk in Rheumatoid Arthritis.

Authors:  Benjamin Demarco; Sara Danielli; Fabian A Fischer; Jelena S Bezbradica
Journal:  Cells       Date:  2022-04-12       Impact factor: 7.666

9.  Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation.

Authors:  Umeharu Ohto; Yukie Kamitsukasa; Hanako Ishida; Zhikuan Zhang; Karin Murakami; Chie Hirama; Sakiko Maekawa; Toshiyuki Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-07       Impact factor: 12.779

10.  Directionality of PYD filament growth determined by the transition of NLRP3 nucleation seeds to ASC elongation.

Authors:  Inga V Hochheiser; Heide Behrmann; Gregor Hagelueken; Juan F Rodríguez-Alcázar; Anja Kopp; Eicke Latz; Elmar Behrmann; Matthias Geyer
Journal:  Sci Adv       Date:  2022-05-13       Impact factor: 14.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.